You know what’s better than silver and gold? PLATINUM. We’re pumped to see this work for Alnylam Pharmaceuticals win the highest honor — a Platinum Award — in the Viddy’s Health & Wellness Commercials category. Surely the first of many shiny things for this campaign. #awards #viddys #pharma
Heartbeat’s Post
More Relevant Posts
-
Specialty Pharmacy Changes can mean a lot of different things to a lot of different companies based on the product type that they may be launching for a successful market access strategy. The commercial success of these unique and sometimes rare products in specialty has different impacts around the distribution channels and services providers need to ensure product access and affordability to their patients. As we move into 2024, we look forward to providing insights and understanding around Specialty Drug distribution that drives the need for a customized product launch strategy for Medical and Pharmacy Benefit. Polaris Specialty Pharmacy and Signio, our Rare and Complex Orphan Division are focused in supporting Specialty Pharmacy and infusion-focused services when working with our pharma partners. If you’d like more information on understanding how your specialty medication will thrive under our unique model, please reach out directly. #specialtypharmacy #pharmacy #orphandrugs #rarediseases #marketaccess #pharma #pharmaceuticalindustry #biopharma Polaris Pharmacy Services Premier Pharmacy Services Doug Albers David Rombro Raquel D. National Association of Specialty Pharmacy (NASP) Pharmacy Podcast Network Jeffrey Hogan
To view or add a comment, sign in
-
BREAKING: Leading drugmakers and pharmacy benefit managers are accused of engaging in a sophisticated scheme to defraud New Yorkers on the costs of #diabetes drugs. Plaintiffs representing the employee health plan of Erie County, N.Y., allege the drug manufacturers—Eli Lilly and Company, Novo Nordisk, and Sanofi—and PBMs—Express Scripts, CVS Caremark, and Optum— colluded with one another to keep the price of insulin high, despite no such market forces, resulting in increased profits at the cost of taxpayers. According to the lawsuit, several instances of lockstep price increases of #insulin drugs occurred shortly after pharmaceutical industry executives and PBMs met in private rooms at industry conferences. For example, the plaintiffs claim that Sanofi increased the list price of its blockbuster insulin drug Lantus by 3% just days after drugmakers hosted private rooms with competitors at a Pharmaceutical Care Management Association conference in 2017. You can read more in my story below: #drugpricing #pbm #pharma #pharmacy #diabetesawareness #diabetesmanagement
To view or add a comment, sign in
-
If you have a self-funded health plan, you work with a Pharmacy Benefits Manager to handle your prescription benefits. Chances are also high that more than half of your annual drug spend comes from "Specialty" drugs that treat chronic conditions and are most often injectable. CVS Caremark has fired the first significant shot in terms of lowering the cost of one of the most prescribed drugs on the market today by replacing it with a Biosimilar. Humira is used to treat Rheumatoid Arthritis as well as Psoriatic Arthritis and Crohn's Disease to name a few. At a cost of $6000 per month or thereabouts, it's quite a significant cost for most plans. Read the attached article to hear more about Biosimilars, what they are and their impact on reducing future costs. #rxcosts #runawaydrugcosts #costimpact #rxhelp #biosimilars #rxinnovation #pharmacybenefitmanagers #pharmacybenefits #pbm #lowerrxcost #hubinternational
CVS Caremark Removes Humira From Formulary: What It Means For The Market | Pharmaceutical Strategies Group (PSG)
psgconsults.com
To view or add a comment, sign in
-
Liptis Favors Fostering Healthier communities by adding values to our community This Indicates healthy business growth, Customer Centricity, Community integration. Being Part of the community means adding positive impact to individuals' health By Healthcare Providers Educational Programs. Quality products and affordable prices (The Winning Equation) #Liptis #healthcare
In 2023, Liptis Pharmaceuticals marked a pivotal moment by adding a new chapter to our success story. Our journey is more than milestones; it's about people. At Liptis, we are dedicated to fostering healthier communities, where every individual's well-being is prioritized. Together, we're not just building success, but also creating a positive impact that extends beyond our organization. #Liptis #Liptispharma
To view or add a comment, sign in
-
Empowering supply chain professionals to optimize networks🚚, sustainability🌱, costs💰, inventory allocation 📉 , and warehouse footprint! 🌍💼 #SupplyChainOptimization
Eli Lilly and Company is disrupting the pharma space with LillyDirect, its new telehealth prescription service and home delivery program for its anti-obesity drug Zepbound and other medications 💊🚀. This bold move gives Lilly a fresh role in the supply chain, becoming a competitor to companies like WeightWatchers and pharmacies. According to The Wall Street Journal, this service aims to streamline the prescription process while ensuring consistent access to medicines, bypassing issues with shortages, knockoffs, and marked-up prices seen in pharmacies 🎯📈. Additionally, LillyDirect will extend Lilly's savings programs and discounts to patients, adding value to their experience 💰💡. As SCM managers, we can learn from this strategy for bringing products directly to customers, enhancing their experience and controlling the supply chain better 🌐🔄. If you find this interesting, please like or share! 🙏 #PharmaInnovation #Telehealth #SupplyChainManagement #DirectDelivery #EliLilly https://lnkd.in/e6GCkwrh
You Can Now Get Weight-Loss Drugs Right From Eli Lilly
wsj.com
To view or add a comment, sign in
-
Zamann and Sanofi expand their collaboration throughout 2024. We're thrilled to announce our expanded collaboration with Sanofi throughout 2024, marking a significant milestone in our journey to set new industry benchmarks. Together, we're tackling one of the most pressing global challenges in pharmaceutical safety: protecting patients from nitrosamines. Nitrosamines, known for their potential health risks, have been a growing concern in the pharma world. Our joint venture with Sanofi is not just a response to this challenge; it's a proactive stride towards innovation and excellence in product quality. By combining Zamann's industry experience and expertise with Sanofi's global reach and know-how, we're creating robust solutions to detect and eliminate nitrosamines, ensuring the highest safety standards for patients worldwide. This collaboration is a testament to our commitment to patient safety and quality healthcare. We're not just setting new standards; we're redefining them. #ZamannInnovation #PatientSafety #Pharma #GlobalHealthChallenge #NitrosaminesFreeFuture #Nitrosamines
To view or add a comment, sign in
-
Our company is one of the few organization that has the know-how and capabilities to provide holoistic GMP solutions. No matter if CSV, Clinical Trial, Audit Readiness, Device Qualification, Facility Commissioning, LIMS, QMS, EM or other topics - we can support you. One of our newest competency additions is the area of Nitrosamines, where we collaborate with Sanofi to create new procedures and innovative solutions for a complex challenge. ⬇ In the wake of the EMA and FDA's recent directives on nitrosamine impurities, the pharmaceutical industry faces significant challenges. These impurities, potentially present in chemically synthesized drug substances, call for rigorous evaluation, testing, and regulatory compliance. 🌐 At Zamann Pharma Support, we specialize in offering end-to-end project management and expert guidance through every step of this complex process. Our services include: 1️⃣ Risk Evaluation - Strategic planning and resource allocation for Marketing Authorization Holders (MAHs) regarding nitrosamine evaluation. - Implementation of global, regional, or local SOPs aligned with ICH M7 guidelines. - Risk evaluation and prioritization of Drug Products (DP) and Active Pharmaceutical Ingredients (API), ensuring compliance with market demands. - Comprehensive Drug Product and Substance Risk Assessments in collaboration with stakeholders. - Internal training and communication strategies. 2️⃣ Confirmatory Testing - Efficient sample and batch management for DPs, APIs, and reference materials. - Coordination of the analytical workstream. - Analytical testing and result evaluation. - Stakeholder decision-making and investigation planning. 3️⃣ Regulatory Communication and CAPA Implementation - Developing and executing strategies for communication with health authorities. - Implementing and managing Corrective and Preventive Actions (CAPA) plans. 🔍 Our goal is to ensure that pharmaceutical companies not only comply with regulatory requirements but also maintain the highest quality standards for their products. By partnering with Zamann, you gain access to a team of experts dedicated to navigating the complexities of nitrosamine risk assessment and mitigation, protecting both your products and patients. Connect with us to learn more about how we can support your journey towards nitrosamine compliance and excellence in pharmaceutical manufacturing. https://lnkd.in/eBt2Y5_N #Pharmaceuticals #QualityManagement #Nitrosamine #gmp #ICH #Pharma
Zamann and Sanofi expand their collaboration throughout 2024. We're thrilled to announce our expanded collaboration with Sanofi throughout 2024, marking a significant milestone in our journey to set new industry benchmarks. Together, we're tackling one of the most pressing global challenges in pharmaceutical safety: protecting patients from nitrosamines. Nitrosamines, known for their potential health risks, have been a growing concern in the pharma world. Our joint venture with Sanofi is not just a response to this challenge; it's a proactive stride towards innovation and excellence in product quality. By combining Zamann's industry experience and expertise with Sanofi's global reach and know-how, we're creating robust solutions to detect and eliminate nitrosamines, ensuring the highest safety standards for patients worldwide. This collaboration is a testament to our commitment to patient safety and quality healthcare. We're not just setting new standards; we're redefining them. #ZamannInnovation #PatientSafety #Pharma #GlobalHealthChallenge #NitrosaminesFreeFuture #Nitrosamines
To view or add a comment, sign in
-
Did you know, the price of Human insulin, Humalog increased by 1527% since 1997? Texas is suing drug companies & PBM’s for raising insulin prices through Deceptive Trade Practices. Texas alleged drug manufacturers Eli Lilly, Novo Nordisk and Sanofi raise the price of insulin and then pay an undisclosed amount back to PBMs Optum Rx, Express Scripts and CVS Caremark through a quid pro quo agreement. • Humalog: Introduced in 1996 at around $21 per vial, the price increased to nearly $275 per vial by 2019. • Lantus: Priced at $35 per vial in 2001, it rose to around $270 by 2019. • Novolog: Initially launched in 2001 at $40 per vial, the price increased to over $289 per vial by 2019. Will Texas prevail? Will this lawsuit force PBM’s and Drug companies to change their business practices? Share your thoughts. #Healthcare
To view or add a comment, sign in
-
Is Teva Pharmaceuticals entering the Humira #biosimilar market at just the right time? Incumbent AbbVie has been doggedly holding market share in the US (~95% of new prescriptions as of end of March), but this has recently changed after CVS dropped Humira in favour of Sandoz's Hyrimoz, with biosimilar penetration rising to 36% at the start of April. Teva is set to launch its own version - Simlandi - this quarter. CEO Richard Francis said “there's been a change in the market versus last year where there's an appetite to really utilise the benefit that biosimilars bring to the market." The firm also has a deal with Quallent Pharmaceuticals Health, LLC, an affiliate of The Cigna Group’s Evernorth Health Services, to supply its Humira biosimilar under a private label. “There are many different opportunities that are emerging, both in the normal channel and in this private label, and that's evolving almost weekly,” Francis commented. “I don't want to try and predict…whether people are going to mirror other people, because I think it's quite individual. I think the bigger picture, which I am encouraged by, is this appetite for biosimilars as a whole.” Read more in my piece here: https://lnkd.in/e4wrpVJk
To view or add a comment, sign in
-
Thoughts on this? >> Esteve to acquire Perrigo's rare disease pharma business for up to $295M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #pharmaceutical #biotech
Esteve to acquire Perrigo's rare disease pharma business for up to $295M
https://endpts.com
To view or add a comment, sign in
36,566 followers